Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

17.0%

9 terminated/withdrawn out of 53 trials

Success Rate

62.5%

-24.0% vs industry average

Late-Stage Pipeline

11%

6 trials in Phase 3/4

Results Transparency

107%

16 of 15 completed trials have results

Key Signals

10 recruiting16 with results9 terminated

Enrollment Performance

Analytics

Phase 1
23(51.1%)
Phase 2
15(33.3%)
Phase 3
5(11.1%)
Early Phase 1
1(2.2%)
Phase 4
1(2.2%)
45Total
Phase 1(23)
Phase 2(15)
Phase 3(5)
Early Phase 1(1)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (53)

Showing 20 of 53 trials
NCT07451054Phase 1Not Yet Recruiting

CD45BE-HSPC + CART-45 Cells

Role: collaborator

NCT06413498Phase 3Recruiting

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

Role: lead

NCT04989803Phase 1Recruiting

Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma

Role: lead

NCT06539338Phase 1Active Not Recruiting

A Study to Investigate Safety of INT2104 Infusions in Participants Aged 18 Years of Age and Older Who Have B-cell Cancers That Came Back After Previous Treatment

Role: lead

NCT07479797Phase 3Not Yet Recruiting

Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy

Role: lead

NCT07304154Phase 1Recruiting

A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases

Role: lead

NCT05605899Phase 3Active Not Recruiting

Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma

Role: lead

NCT02625480Phase 1Completed

Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Role: lead

NCT05776134Unknown

Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel

Role: lead

NCT06104592Phase 2Recruiting

Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL

Role: collaborator

NCT06144606Phase 2Recruiting

Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Role: collaborator

NCT02601313Phase 2Completed

Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)

Role: lead

NCT07038447Phase 1Enrolling By Invitation

A Study of KITE-363 in Participants With Refractory Autoimmune Diseases

Role: lead

NCT05537766Phase 2Terminated

Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies

Role: lead

NCT04319237Completed

Axicabtagene Ciloleucel:Neurocognitive and Patient-Reported Outcomes

Role: collaborator

NCT05495464Early Phase 1Active Not Recruiting

A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma

Role: collaborator

NCT05041309Enrolling By Invitation

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

Role: lead

NCT04155749Phase 1Active Not Recruiting

Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma

Role: lead

NCT05396885Phase 2Active Not Recruiting

Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)

Role: lead

NCT05459571Phase 2Completed

Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma

Role: lead